

**AMBER PHARM LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021**

Amber Pharm Ltd
Unaudited Financial Statements
For The Year Ended 31 December 2021

Contents

	Page
Balance Sheet	1–2
Notes to the Financial Statements	3–7

Amber Pharm Ltd
Balance Sheet
As at 31 December 2021

Registered number: 12370121

		31 December 2021		31 December 2020	
	Notes	£	£	£	£
FIXED ASSETS					
Intangible Assets	3		1,220,339		814,120
Tangible Assets	4		63,253		11,046
			1,283,592		825,166
CURRENT ASSETS					
Stocks	5	61,798		-	
Debtors	6	398,480		5,659	
Cash at bank and in hand		425,886		5,098	
			886,164		10,757
Creditors: Amounts Falling Due Within One Year	7	(808,605)		(375,729)	
NET CURRENT ASSETS (LIABILITIES)			77,559		(364,972)
TOTAL ASSETS LESS CURRENT LIABILITIES			1,361,151		460,194
Creditors: Amounts Falling Due After More Than One Year	8	(885,118)		(602,444)	
NET ASSETS/(LIABILITIES)			476,033		(142,250)
CAPITAL AND RESERVES					
Called up share capital	10	100		100	
Profit and Loss Account		475,933		(142,350)	
SHAREHOLDERS' FUNDS			476,033		(142,250)

Amber Pharm Ltd
Balance Sheet (continued)
As at 31 December 2021

For the year ending 31 December 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mr Hiren Patel

Director

28/07/2022

Mr Nicky Patel

Director

Mr Baldev Bange

Director

The notes on pages 3 to 7 form part of these financial statements.

Amber Pharm Ltd
Notes to the Financial Statements
For The Year Ended 31 December 2021

1. Accounting Policies

1.1. Basis of Preparation of Financial Statements

The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Section 1A Small Entities - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

1.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

1.3. Intangible Fixed Assets and Amortisation - Goodwill

Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets. It is amortised to profit and loss account over its estimated economic life of 10 years.

1.4. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Motor Vehicles	10% reducing balance
Computer Equipment	25% straight line

1.5. Leasing and Hire Purchase Contracts

Assets obtained under hire purchase contracts and finance leases are capitalised as tangible fixed assets. Assets acquired under finance leases are depreciated over the shorter of the lease term and their useful lives. Assets acquired under hire purchase contracts are depreciated over their useful lives. Finance leases are those where substantially all of the benefits and risks of ownership are assumed by the company. Obligations under such agreements are included in the creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period. Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to profit and loss account as incurred.

1.6. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

Amber Pharm Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2021

1.7. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.

2. Average Number of Employees

Average number of employees, including directors, during the year was as follows: 16 (2020: NIL)

3. Intangible Assets

	Goodwill
	£
Cost	
As at 1 January 2021	880,000
Additions	525,000
As at 31 December 2021	<u>1,405,000</u>
Amortisation	
As at 1 January 2021	65,880
Provided during the period	118,781
As at 31 December 2021	<u>184,661</u>
Net Book Value	
As at 31 December 2021	<u>1,220,339</u>
As at 1 January 2021	<u>814,120</u>

The addition to goodwill arose on the purchase of the share capital of Eccleshall Pharmacy Ltd.

Amber Pharm Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2021

4. Tangible Assets

	Motor Vehicles	Computer Equipment	Total
	£	£	£
Cost			
As at 1 January 2021	-	11,176	11,176
Additions	52,990	2,826	55,816
As at 31 December 2021	52,990	14,002	66,992
Depreciation			
As at 1 January 2021	-	130	130
Provided during the period	247	3,362	3,609
As at 31 December 2021	247	3,492	3,739
Net Book Value			
As at 31 December 2021	52,743	10,510	63,253
As at 1 January 2021	-	11,046	11,046

5. Stocks

	31 December 2021	31 December 2020
	£	£
Stock - materials	61,798	-
	61,798	-

6. Debtors

	31 December 2021	31 December 2020
	£	£
Due within one year		
Trade debtors	332,611	-
Other debtors	19,502	433
Other taxes and social security	-	5,226
Amounts owed by subsidiaries	46,367	-
	398,480	5,659

Amber Pharm Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2021

7. Creditors: Amounts Falling Due Within One Year

	31 December 2021	31 December 2020
	£	£
Net obligations under finance lease and hire purchase contracts	9,091	-
Trade creditors	227,840	27,816
Bank loans and overdrafts	101,060	61,900
Other taxes and social security	174,813	-
Other creditors	98,801	70,655
Amounts owed to subsidiaries	-	118,358
Amounts owed to associates	197,000	97,000
	<u>808,605</u>	<u>375,729</u>

8. Creditors: Amounts Falling Due After More Than One Year

	31 December 2021	31 December 2020
	£	£
Net obligations under finance lease and hire purchase contracts	36,512	-
Bank loans	848,606	602,444
	<u>885,118</u>	<u>602,444</u>

A HSBC loan of £367,500 was received in May 2021 in relation to the Ecceshall Pharmacy purchase. Repayments began in June 2021.

9. Obligations Under Finance Leases and Hire Purchase

	31 December 2021	31 December 2020
	£	£
The maturity of these amounts is as follows:		
Amounts Payable:		
Within one year	9,091	-
Between one and five years	36,512	-
	<u>45,603</u>	<u>-</u>
	<u>45,603</u>	<u>-</u>

10. Share Capital

	31 December 2021	31 December 2020
Allotted, Called up and fully paid	<u>100</u>	<u>100</u>

Amber Pharm Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2021

11. Related Party Transactions

The company owes £197,000 to NH Pharm Ltd. Nicky Patel is a director and shareholder of this company.

The company owes £96,900 to Baldev Bange a director and shareholder of this company.

The company is owed £46,367 by its subsidiary Eccleshall Pharmacy Ltd.

12. General Information

Amber Pharm Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12370121 . The registered office is 4 Emmanuel Court, Reddicroft, Sutton Coldfield, West Midlands, B73 6AZ.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.